Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21441827 | 1.00 | GBA1 (0.41) | GBA1HTR1AOPRK1SPHK2SPHK1 | |
| SCHEMBL17979137 | 1.00 | GBA1 (0.41) | GBA1HTR1AOPRK1SPHK2SPHK1 | |
| SCHEMBL22443654 | 0.89 | GBA1 (0.38) | GBA1HTR1AOPRK1SPHK2SPHK1 | |
| SCHEMBL22443656 | 0.89 | GBA1 (0.38) | GBA1HTR1AOPRK1SPHK2SPHK1 | |
| SCHEMBL22444194 | 0.82 | SIGMAR1 (0.42) | GBA1HTR1ASIGMAR1ACHE | |
| SCHEMBL22444151 | 0.82 | SIGMAR1 (0.42) | GBA1HTR1ASIGMAR1ACHE | |
| SCHEMBL22443386 | 0.76 | SPHK2 (0.41) | GBA1SPHK2SPHK1SIGMAR1ACHE | |
| SCHEMBL29585107 | 0.76 | CCR3 (0.41) | OPRL1 | |
| SCHEMBL22443385 | 0.76 | SPHK2 (0.41) | GBA1SPHK2SPHK1SIGMAR1ACHE | |
| SCHEMBL960491 | 0.73 | CHRM2 (0.47) | GBA1SPHK2SPHK1SIGMAR1FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565587-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B Technologies (Beijing) Co., Limited (CN) | 2025-06-11 | — | — | EP | disclosed |
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2024027116-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | PLA2G4A, PLA2G1B, PLA2G4B | GBA1 186/4885HTR1A 2036/4885OPRK1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.